The trial by Pinto-Sanchez et al1 published in a recent issue of Gastroenterology reports a relationship between probiotic Bifidobacterium longum NCC3001 and a decrease in depression scores in patients with irritable bowel syndrome (IBS). IBS is considered a gut–brain disorder and, thus, many patients with IBS experience depression and anxiety symptoms.2–4 Therefore, the results of this trial could be far reaching for people with IBS and lead to an increased use of probiotics with Bifidobacterium longum NCC3001.